Thermo Fisher Scientific

Equities

TMO

US8835561023

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:02 2024-07-17 pm EDT			5-day change	1st Jan Change
555.1 ^USD	-0.06%		+3.39%	+4.57%

Jul. 16	Orthofix Names Stephanie Walsh as Chief Human Resources Officer	CI
Jul. 11	Thermo Fisher Scientific Keeps Quarterly Cash Dividend at $0.39 Per Share, Payable Oct. 15 to Holders as of Sept. 13	MT

Tranche Update on Thermo Fisher Scientific Inc.'s Equity Buyback Plan announced on November 10, 2022.

January 30, 2024

From October 1, 2023 to November 14, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 5,222,234 shares, representing 1.34% for $3,000.02 million under the buyback announced on November 10, 2022.

Latest news about Thermo Fisher Scientific

Orthofix Names Stephanie Walsh as Chief Human Resources Officer	Jul. 16	CI
Thermo Fisher Scientific Keeps Quarterly Cash Dividend at $0.39 Per Share, Payable Oct. 15 to Holders as of Sept. 13	Jul. 11	MT
Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on October 15, 2024	Jul. 11	CI
Thermo Fisher Scientific to Work With National Cancer Institute to Advance Research on New Treatments	Jul. 11	MT
Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology	Jul. 11	CI
Thermo Fisher Scientific Completes Acquisition of Olink	Jul. 10	MT
Thermo Fisher Scientific Inc. completed the acquisition of Olink Holding AB from Summa Equity AB and others.	Jul. 09	CI
Thermo Fisher Scientific Opens Its First Electron Microscopy Demo Center in Taiwan	Jul. 09	CI
Olink Holding Receives UK Approval for Thermo Fisher's $26 per Share Tender Offer	Jul. 08	MT
UK Competition Watchdog Clears Thermo Fisher Scientific's Purchase of Sweden's Olink	Jul. 08	MT
UK's competition regulator clears $3.1 billion Thermo Fisher Scientific-Olink deal	Jul. 08	RE
Evercore ISI Cuts Price Target on Thermo Fisher Scientific to $600 From $615, Maintains Outperform Rating	Jul. 02	MT
Verici Dx hails milestone payment in deal with Thermo Fisher	Jul. 01	AN
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell Top 200 Growth Index	Jun. 30	CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 3000 Growth Index	Jun. 30	CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 3000E Growth Index	Jun. 30	CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth Index	Jun. 30	CI
Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth-Defensive Index	Jun. 30	CI
Thermo Fisher Scientific Inc. Expands Clinical Research Laboratory in Kentucky	Jun. 27	CI
Barclays Adjusts Price Target on Thermo Fisher Scientific to $600 From $615	Jun. 27	MT
Labguru Announces New Distribution Partnership with Thermo Fisher Scientific of its Electronic Lab Notebook Module to Help Streamline Life Sciences Research	Jun. 26	CI
Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies	Jun. 25	CI
RBC Trims Price Target on Thermo Fisher Scientific to $660 From $662, Keeps Outperform Rating	Jun. 24	MT
Thermo Fisher Scientific Inc. Expands Clinical Research Laboratory in Wisconsin	Jun. 18	CI
Thermo Fisher Scientific Inc., National University Hospital, Singapore and Mirxes Collaborates to Enhance Access to Advanced Genomic Testing for Early Cancer Detection in Singapore	Jun. 18	CI

Chart Thermo Fisher Scientific

Duration

Period

More charts

Company Profile

Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (70%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - diagnostics equipment and products (15.3%); - scientific analysis equipments (14.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc. Net sales break down by source of income into products sales (78.5%) and services (21.5%). Net sales break down geographically as follows: North America (53%), Europe (25.7%), Asia-Pacific (18.1%) and others (3.2%).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-24 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Thermo Fisher Scientific

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

555.1 USD

Average target price

628.2 USD

Spread / Average Target

+13.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+4.57%	212B
DANAHER CORPORATION	+8.61%	186B
INTUITIVE SURGICAL, INC.	+26.34%	151B
BOSTON SCIENTIFIC CORPORATION	+33.90%	114B
SIEMENS HEALTHINEERS AG	+3.04%	65.57B
EDWARDS LIFESCIENCES CORPORATION	+14.50%	52.61B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	46.8B
AGILENT TECHNOLOGIES, INC.	-3.98%	38.95B
GE HEALTHCARE TECHNOLOGIES INC.	+6.66%	37.64B
RESMED, INC.	+19.72%	30.25B

Other Advanced Medical Equipment & Technology